The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is offering this grant to conduct a comprehensive study aimed at understanding the pathophysiology and clinical course of new-onset diabetes that develops after SARS-CoV-2 infection. This grant is for establishing a diverse, longitudinal cohort, including both children and adults representative of the U.S. population, alongside a suitable comparator group. The research will investigate how specific biological pathways, the pandemic’s overall health impact, COVID-19 severity, and its treatments contribute to excess new-onset diabetes and influence treatment response. NIDDK strongly encourages applications addressing sex/gender differences, sexual and gender minority-related research, and race/ethnic diversity, aligning with its mission to reduce health disparities.
Opportunity ID: 342247
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-22-016 |
| Funding Opportunity Title: | Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 13, 2022 |
| Last Updated Date: | Jul 13, 2022 |
| Original Closing Date for Applications: | Dec 20, 2022 |
| Current Closing Date for Applications: | Dec 20, 2022 |
| Archive Date: | Jan 25, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $3,750,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Private institutions of higher education City or township governments State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Small businesses County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement invites applications to conduct a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID diabetes. The cohort must include children and adults and reflect the geography and demographics of COVID-19 in the U.S. There must be an appropriate comparator population recruited and followed. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy.The NIDDK strongly encourages Research on Sex/Gender Differences, Sexual and Gender Minority-Related Research and Race/Ethnic Diversity (see NOT-DK-22-003). This FOA aligns with the Mission and Vision of the NIDDK Strategic Plan for Research, including the theme of empowering a multidisciplinary workforce, engaging diverse stakeholders, and pursuing pathways to health for all. Specifically, this FOA aligns with the Scientific Goals (1.1 and 1.2) and Cross-cutting Topics (reducing health disparities and increasing health equity among racial and ethnic minority populations and others who are underserved) of the Strategic Plan. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-016.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 342247 Full Announcement-RFA-DK-22-016 -> RFA-DK-22-016-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00275892 | Nov 20, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277982 | Nov 20, 2022 | Dec 20, 2022 | View |
Package 1
Mandatory forms
342247 RR_SF424_5_0-5.0.pdf
342247 PHS398_CoverPageSupplement_5_0-5.0.pdf
342247 RR_OtherProjectInfo_1_4-1.4.pdf
342247 PerformanceSite_4_0-4.0.pdf
342247 RR_KeyPersonExpanded_4_0-4.0.pdf
342247 PHS398_ResearchPlan_4_0-4.0.pdf
342247 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342247 RR_Budget_3_0-3.0.pdf
342247 RR_SubawardBudget30_3_0-3.0.pdf
342247 PHS398_ModularBudget_1_2-1.2.pdf
342247 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
342247 RR_SF424_5_0-5.0.pdf
342247 PHS398_CoverPageSupplement_5_0-5.0.pdf
342247 RR_OtherProjectInfo_1_4-1.4.pdf
342247 PerformanceSite_4_0-4.0.pdf
342247 RR_KeyPersonExpanded_4_0-4.0.pdf
342247 PHS398_ResearchPlan_5_0-5.0.pdf
342247 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342247 RR_Budget_3_0-3.0.pdf
342247 RR_SubawardBudget30_3_0-3.0.pdf
342247 PHS398_ModularBudget_1_2-1.2.pdf
342247 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
